---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-016497"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:46:15.115939+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance

## Summary
- Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).
- Organic base business sales grew 10.8% YoY; fifth consecutive double-digit quarter.
- FY2024 adjusted EPS guidance raised to $4.55-$4.70 midpoint; organic sales growth 8.5%-10.0% ex-COVID tests.
- Medical Devices organic sales +14.3%; FreeStyle Libre revenue $1.5B (+22.4% reported).
- FDA approved TriClip for tricuspid regurgitation and i-STAT TBI test; quarterly dividend $0.55/share maintained.

## SEC filing metadata
- accession: 0001628280-24-016497
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/abt-20240417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-016497
- JSON: https://secwatch.observer/filing/0001628280-24-016497.json
- Plain text: https://secwatch.observer/filing/0001628280-24-016497.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES reported the first quarter ended March 31, 2024 results: revenue $10.0 billion, EPS $0.70. Guidance raised.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $10.0 billion
  - EPS: $0.70
  - Guidance: raised
  - Result: reported results
  source text: Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year – Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth 1 ABBOTT PARK, Ill., April 17, 2024 — Abbott today announced financial results for the first quarter ended March 31, 2024. • First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.